Thursday, May 26, 2022

Swiss researchers begin trials for a COVID-19 “patch” vaccine

Volunteer Julian Oppliger rests after receiving a new-generation COVID-19 vaccine administered via an arm patch during a phase I clinical study led by Unisante at the University Hospital in Lausanne, Switzerland, January 19, 2022.Cecil Mantovani/Reuters

Swiss medical researchers on Wednesday said they have launched an early-stage study to test a next-generation COVID-19 vaccine candidate, which will be administered via an arm patch, to look at alternative methods of injecting. Latest for .

Unlike conventional vaccines that stimulate antibody production, the new PepGNP-Covid19 vaccine candidate focuses on T-cells, which are responsible for cellular immunity, to eliminate virus-infected cells and prevent it from replicating. Can you

British company Emerges Vaccines Holding Ltd has developed the potential vaccine, while Unicent Medical Research Center in Lausanne in collaboration with the city’s CHUV Hospital will run the trials, which began on January 10.

Read Also:  Coronavirus Wednesday updates: 40 more deaths reflect impact of latest surge

Professor Blaise Genton, who led the study, said this cellular immunity generates so-called “memory cells”, which could make the vaccine more durable and better than others at protecting against potential forms of the virus.

The potential vaccine will be administered through micro-needles in patches less than a millimeter deep, which they hope will provide long-term immunity to COVID-19 and remove the need for seasonal booster shots.

“With this new vaccine that generates this cellular immunity, we hope to have a longer period of protection … we don’t know yet, but it could be a year, two years, three years,” Genton told Reuters.

To administer the vaccine, the patch will be briefly pressed against the skin and then removed.

Read Also:  Contagious Omicron subvariant BA.2 spreading quickly as restrictions are lifted: US experts

The study is the first in the world with the new candidate and uses the same technology, following the start of another study last year in Lausanne to assess the safety of a new generation dengue vaccine.

Emergex Vaccines Holding Ltd announced in November that it would begin testing a COVID-19 vaccine. The company did not immediately respond to a request for comment.

Pharmaceutical companies are developing other ways to deliver vaccines. India’s Bharat Biotech and partners Codagenix Inc and Serum Institutes of India are each trialing a nasal COVID-19 vaccine candidate.

The PepGNP-Covid19 researchers began vaccinating 26 volunteers last week and plan to give them two doses — a base dose and a slightly stronger one. They will follow the volunteers for six months.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a brief summary of the day’s most important headlines. Sign up today,

,

Nation World News Desk
Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -